Clinical Trial Update: Pazopanib Vs. Pazopanib Plus Gemcitabine [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing pazopanib alone versus pazopanib plus gemcitabine for leiomyosarcoma or carcinosarcoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinosarcoma
• Leiomyosarcoma

Drugs mentioned

• Gemzar (gemcitabine)
• Votrient (Pazopanib)

Snippet

Sponsor: North Eastern German Society of Gynaecological Oncology | Conditions: Leiomyosarcoma or Carcinosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING